Lactobacillus reuteri Ameliorates Intestinal Inflammation and Modulates Gut Microbiota and Metabolic Disorders in Dextran Sulfate Sodium-Induced Colitis in Mice

Gang Wang,Shuo Huang,Shuang Cai,Haitao Yu,Yuming Wang,Xiangfang Zeng,Shiyan Qiao

DOI: https://doi.org/10.3390/nu12082298

IF: 5.9

2020-07-31

Nutrients

Abstract:Lactobacillus reuteri, a commensal intestinal bacteria, has various health benefits including the regulation of immunity and intestinal microbiota. We examined whether L. reuteri I5007 could protect mice against colitis in ameliorating inflammation, modulating microbiota, and metabolic composition. In vitro, HT-29 cells were cultured with L. reuteri I5007 or lipopolysaccharide treatment under three different conditions, i.e., pre-, co- (simultaneous), and posttreatment. Pretreatment with L. reuteri I5007 effectively relieves inflammation in HT-29 cells challenged with lipopolysaccharide. In vivo, mice were given L. reuteri I5007 by gavage throughout the study, starting one week prior to dextran sulfate sodium (DSS) treatment for one week followed by two days without DSS. L. reuteri I5007 improved DSS-induced colitis, which was confirmed by reduced weight loss, colon length shortening, and histopathological damage, restored the mucus layer, as well as reduced pro-inflammatory cytokines levels. Analysis of 16S rDNA sequences and metabolome demonstrates that L. reuteri I5007 significantly alters colonic microbiota and metabolic structural and functional composition. Overall, the results demonstrate that L. reuteri I5007 pretreatment could effectively alleviate intestinal inflammation by regulating immune responses and altering the composition of gut microbiota structure and function, as well as improving metabolic disorders in mice with colitis.

nutrition & dietetics

What problem does this paper attempt to address?

The problem that this paper attempts to solve is to evaluate the role of Lactobacillus _reuteri_ I5007 (an intestinal symbiotic bacterium) in alleviating dextran sulfate sodium (DSS) - induced colitis in mice, specifically including its regulatory effects on intestinal inflammation, microbial community and metabolic disorders. Through in vitro experiments (using the HT - 29 cell model) and in vivo experiments (using the DSS - induced colitis mouse model), the study explored whether pretreatment with L. reuteri I5007 can effectively reduce intestinal inflammation, regulate the immune response, change the structural and functional composition of the intestinal microbiota, and improve metabolic disorders.